AR054285A1 - Sal cristalina de derivado de 2-oxo-quinolina, agonista de beta 2 adrenergico, proceso y uso - Google Patents
Sal cristalina de derivado de 2-oxo-quinolina, agonista de beta 2 adrenergico, proceso y usoInfo
- Publication number
- AR054285A1 AR054285A1 AR20060102492A ARP060102492A AR054285A1 AR 054285 A1 AR054285 A1 AR 054285A1 AR 20060102492 A AR20060102492 A AR 20060102492A AR P060102492 A ARP060102492 A AR P060102492A AR 054285 A1 AR054285 A1 AR 054285A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxo
- beta
- adrenergic agonist
- quinoline derivative
- crystal salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Abstract
La presente se refiere a la preparacion de un agonista beta2 adrenérgico en forma de sal cristalina. En particular se refiere a una sal cristalina de N-[2-[4-[(3-fenil-4-metoxifenil)amino]fenil]etil]-( R )-2-hidroxi-2-(8-hidroxi-1,2-dihidro-2- oxoquinolin-5-il)etilamina. Reivindicacion 2: Una sal 2,5-diclorobencenosulfonato del compuesto de formula (1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0512246.0A GB0512246D0 (en) | 2005-06-15 | 2005-06-15 | Novel pharmaceutical |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054285A1 true AR054285A1 (es) | 2007-06-13 |
Family
ID=34855626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20060102492A AR054285A1 (es) | 2005-06-15 | 2006-06-13 | Sal cristalina de derivado de 2-oxo-quinolina, agonista de beta 2 adrenergico, proceso y uso |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090227547A1 (es) |
EP (1) | EP1893580A1 (es) |
JP (1) | JP2008546659A (es) |
AR (1) | AR054285A1 (es) |
GB (1) | GB0512246D0 (es) |
PE (1) | PE20070079A1 (es) |
TW (1) | TW200716554A (es) |
WO (1) | WO2006133942A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012515148A (ja) | 2009-01-13 | 2012-07-05 | グラクソ グループ リミテッド | Sykキナーゼ阻害剤としてのピリミジンカルボキサミド誘導体 |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060712B2 (en) * | 2003-05-08 | 2006-06-13 | Theravance, Inc. | Crystalline form of aryl aniline β2 adrenergic receptor agonist |
-
2005
- 2005-06-15 GB GBGB0512246.0A patent/GB0512246D0/en not_active Ceased
-
2006
- 2006-06-13 JP JP2008516234A patent/JP2008546659A/ja active Pending
- 2006-06-13 EP EP06754385A patent/EP1893580A1/en not_active Withdrawn
- 2006-06-13 AR AR20060102492A patent/AR054285A1/es not_active Application Discontinuation
- 2006-06-13 TW TW095121018A patent/TW200716554A/zh unknown
- 2006-06-13 PE PE2006000659A patent/PE20070079A1/es not_active Application Discontinuation
- 2006-06-13 WO PCT/EP2006/005763 patent/WO2006133942A1/en active Application Filing
- 2006-06-13 US US11/917,190 patent/US20090227547A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200716554A (en) | 2007-05-01 |
EP1893580A1 (en) | 2008-03-05 |
GB0512246D0 (en) | 2005-07-27 |
US20090227547A1 (en) | 2009-09-10 |
WO2006133942A1 (en) | 2006-12-21 |
PE20070079A1 (es) | 2007-02-08 |
JP2008546659A (ja) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045317A1 (es) | Forma cristalina de agonista dl receptor adrenergico b2 | |
AR104566A2 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
NZ592533A (en) | METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR | |
UY30136A1 (es) | Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona | |
AR053169A1 (es) | Metabolitos de n-2 (cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil) -2-metil -4-pi rimidinil] amino]-5-tiazol carboxamidas | |
CL2007002930A1 (es) | Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
BR112013025881A2 (pt) | composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii) | |
AR054445A1 (es) | Formulaciones de un inhibidor de src/abl | |
BRPI0510231A (pt) | composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo | |
PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
PE20090423A1 (es) | Compuestos moduladores de sirtuina | |
BRPI0514372A (pt) | inibidores de tiazol de frutose 1, 6-bisfosfatase | |
CY1109072T1 (el) | Βητα κρυσταλλικη μορφη του υδροχλωρικου αλατος της ιβαμπραδινης, μεθοδος παρασκευης αυτου και φαρμακευτικης συνθεσεις που το περιεχουν | |
RU2012123372A (ru) | Гетероциклические модуляторы транспортеров атф-связывающей кассеты | |
BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
BRPI0515081B8 (pt) | composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida | |
MY151295A (en) | Pyrimidyl indoline compound | |
CO6361988A2 (es) | Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina. | |
AR051796A1 (es) | Derivados de hidantoina como inhibidores de metaloproteinasas | |
AR068187A1 (es) | Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv | |
EA201270099A1 (ru) | Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота | |
PE20071062A1 (es) | Antibioticos de carbonatos de fenicol | |
ECSP10010576A (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
AR054285A1 (es) | Sal cristalina de derivado de 2-oxo-quinolina, agonista de beta 2 adrenergico, proceso y uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |